News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire launches potential blockbuster dry eye drug in US Xiidra could be ophthalmology blockbuster.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.